Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Safety and efficacy of initiating highly active anti retroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa
Journal of Acquired Immune Deficiency Syndromes, Volume 49, No. 3, Year 2008
Notification
URL copied to clipboard!
Description
Objective describe the safety and efficacy of highly active antiretroviral therapy (HAART) in pregnant women treated in an integrated antiretroviral antenatal clinic (ANC ARV). Methods: A retrospective analysis was performed on patients attending the ANC ARV from August 2004 through February 2007. Results: Data were collected on 689 treatment-naive pregnant women initiated on HAART. The mean age was 29.2 years. The mean baseline CD4 + count was 154 cells per microliter, and mean baseline HIV viral load was 101,561 copies per milliliter. Tuberculosis was the most prevalent presenting opportunistic infection (7.7%). Stavudine, lamivudine, and nevirapine were initiated in 82% of women with the most frequent adverse drug reaction being nevirapine-associated skin rash (3.5%). Mean gestational age at HAART initiation was 27 weeks. Among women with follow-up data, 80% gained 50 or more CD4 cells per microliter and 80.5% achieved viral suppression to <1000 copies per milliliter. Of 302 mother-infant pairs who completed postnatal follow-up, the HIV transmission rate was 5%. In women who received more than 7 weeks of HAART during pregnancy, transmission was 0.3%. Conclusions: Within the ANC ARV program, initiating pregnant women on HAART was feasible, safe, and effective. Advanced gestational age at treatment initiation and loss to follow-up emerge as important challenges in this population. Copyright © 2008 Lippincott Williams & Wilkins.
Authors & Co-Authors
Black, V.
South Africa, Johannesburg
University of the Witwatersrand
Hoffman, Risa M.
United States, Los Angeles
University of California, Los Angeles
United States, Los Angeles
David Geffen School of Medicine at Ucla
Sugar, Catherine A.
United States, Los Angeles
Ucla Fielding School of Public Health
Menon, Priya
South Africa, Johannesburg
University of the Witwatersrand
Venter, François W.D.
South Africa, Johannesburg
University of the Witwatersrand
Currier, Judith Silverstein
United States, Los Angeles
University of California, Los Angeles
Rees, Helen V.
South Africa, Johannesburg
University of the Witwatersrand
Statistics
Citations: 57
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1097/QAI.0b013e318189a769
ISSN:
15254135
Research Areas
Health System And Policy
Infectious Diseases
Maternal And Child Health
Sexual And Reproductive Health
Study Design
Cross Sectional Study
Cohort Study
Study Locations
South Africa
Participants Gender
Female